That gives us some clarity on when we can expect OTCQB to contact Kiwa Biotech and take action by September 30th.
"Beginning September 1, 2020, deficiency notices will be sent to companies not in compliance with these standards providing 30 days in which to regain compliance."
Hopefully, Kiwa management will resolve the compliance issues in August to avoid this process.
"Companies and their representatives are encouraged to contact Issuer Services with questions or matters of particular concern. OTC Markets Group will review each company’s unique circumstances and may provide additional relief based on a reasonable written plan of compliance on a case-by-case basis."